Becker's Analysis Examines Health System Preparedness for Cell and Gene Therapy Scale-Up

In a commentary piece, Becker's Hospital Review examines operational challenges health systems face as the cell and gene therapy pipeline expands beyond rare disease applications into broader patient populations. With more than 35 FDA-approved cell and gene therapies now on the market and additional approvals expected, the article explores infrastructure, workflow, and care delivery model changes required to administer these treatments at scale. The piece is oriented toward hospital systems and does not address Medicaid-specific coverage, reimbursement, or managed care contract implications for these therapies. While Medicaid programs and managed care organizations will eventually confront CGT coverage and payment policy questions as utilization grows, this particular analysis focuses on provider delivery system readiness without Medicaid program context.